TABLE 2.
Binding and neutralization EC50 concentrations for anti-HPV type-specific MAbs
| MAb | HPV type(s) and epitopea | HPV type(s) neutralized | EC50 (ng/ml) |
|
|---|---|---|---|---|
| Binding | Neutralizing | |||
| H31.5F12 | 31 | 31 | 4.1 | 5.2 |
| H31.5D10 | 31 | 31 | 3.6 | 9.1 |
| H33.5D4 | 33 | 33 | 2.3 | 0.39 |
| H33.6G9 | 33 | 33 | 2.3 | 0.38 |
| H45.6G6 | 45, 18 | 45, 18 | 1.7 (HPV45), 13 (HPV18) | 0.35 (HPV45), 270 (HPV18) |
| H45.10B4 | 45 | 45 | 4.9 | 12 |
| H52.8D11 | 52 | 52 | 4.0 | 0.49 |
| H52.9F7 | 52 | 52 | 3.4 | 0.41 |
| H58.2C3 | 58 | 58 | 2.2 | 1.1 |
| H58.6E11 | 58 | 58 | 2.1 | 1.7 |
All are conformational.